Clinical Trials Browser

Phase 2 × Lung Neoplasms × E-3810 × Clear all

NCT02109016 2019-07-29

A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma